Yes. Symeres is owned by private equity investor Keensight Capital.
Symeres is headquartered in Nijmegen, Netherlands.
Symeres is a life science company.
Symeres is a mid-sized European Contract Research Organization for drug discovery and development needs. The company offers best-in-class solutions for drug discovery and drug development for small molecules and beyond. Their services span from preclinical hit finding all the way to the delivery of early clinical phase drug substance API. Symeres blends a deep scientific knowledge base with creativity and problem-solving skills to deliver the quality results that clients need. Symeres is based in Nijmegen, Netherlands.
| Year | ≤ '20 | '21 | '22 | '23 | '24 | '25 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (0.4/yr) | # | - | - | 2 | - | - | - | 2 |
| Sell (0.0/yr) | # | - | - | - | - | - | - | 0 |
| 2 | ||||||||
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
